臨床外科60巻2号

2005年02月発行

特集 再発食道癌を考える

再発食道癌に対する遺伝子治療・免疫治療の可能性

著者： 島田英昭¹ 落合武徳¹

所属機関： ¹千葉大学大学院医学研究院先端応用外科学

ページ範囲：P.207 - P.213

文献概要

要旨：固形癌に対する遺伝子治療ならびに免疫治療は臨床研究が始まったばかりではあるが，安全性が確認されつつある．筆者らは放射線化学療法治療抵抗性の再発・再燃食道癌10症例に対してアデノウイルスベクターを用いたp53遺伝子治療を実施し，安全性ならびに腫瘍増殖の抑制傾向を確認した．食道癌に対する免疫治療臨床研究では腫瘍抗原特異的免疫反応が確認され，一部の症例では有効性も示唆されている．今後，遺伝子治療・免疫治療を統合した新たな治療戦略の発展が期待される．

参考文献

1）Shimada H, Kitabayashi H, Nabeya Y, et al：Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery 133：24-31, 2003

2）Kobayashi S, Koide Y, Endo M, et al：The p53gene mutation is of prognostic value in esophageal squamous cell carcinoma patients in unified stages of curability. Am J Surg 177：497-502, 1999

3）Oota M, Takeda A, Shimada H, et al：Prognostic significance of thymidine phosphorylase and p53 co-expression in esophageal squamous cell carcinoma. Oncology Reports 9：23-28, 2002

4）Shimada H, Nabeya Y, Okazumi S, et al：Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery 132：41-47, 2003

5）Shimada H, Okazumi S, Takeda A, et al：Presence of serum p53 antibodies is associated with decreased in vitro chemosensitivity in patients with esophageal cancer. Surg Today 31：591-596, 2001

6）Shimada H, Shimizu T, Ochiai T：Preclinical study of adenoviral p53gene therapy for esophageal cancer. Surg Today 31：597-604, 2001

7）Shimada H, Matsubara H, Ochiai T：p53gene therapy for esophageal cancer. J Gastroenterol 37：87-91, 2002

8）Mukai M, Kubota S, Morita S, et al：A pilot study of combination therapy of radiation and local administration of OK-432 for esophageal cancer―Five-year survival and local control rate. Cancer 75：2276-2280, 1995

9）Ogoshi K, Satou H, Isono K, et al：Immunotherapy for esophageal cancer―A randomized trial in combination with radiotherapy and radiochemotherapy. Co-operative Study Group for Esophageal Cancer in Japan. Am J Clin Oncol 18：216-222, 1995

10）Temeck BK, Liebmann JE, Theodossiou C, et al：PhaseⅡtrial of 5-fluorouracil, leucovorin, interferon-alpha-2a, and cisplatin as neoadjuvant chemotherapy for locally advanced esophageal carcinoma. Cancer 77：2432-2439, 1996

11）Ueda Y, Yamagishi H, Tanioka Y, et al：Clinical application of adoptive immunotherapy and IL-2 for the treatment of advanced digestive tract cancer. Hepatogastroenterology 46：1274-1279, 1999

12）Toh U, Yamana H, Sueyoshi S, et al：Locoregional cellular immunotherapy for patients with advanced esophageal cancer. Clin Cancer Res 6：4663-4673, 2000

13）Yoshitake Y, Nakatsura T, Monji M, et al：Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using comple-mentary DNA microarray analysis. Clin Cancer Res 10：6437-6448, 2004

14）Chen YT, Scanlan MJ, Sahin U, et al：A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94：1914-1918, 1997

15）Tanaka F, Fujie T, Tahara K, et al：Induction of anti-tumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. Cancer Res 57：4465-4468, 1997

16）Kikuchi M, Nakao M, Inoue Y, et al：Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lympho-cytes. Int J Cancer 81：459-466, 1999

17）Nakashima K, Shimada H, Ochiai T, et al：Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer 112：1029-1035, 2004

18）Shimada H, Nakashima K, Ochiai T, et al：Serological identification of tumor antigens of esophageal squamous cell carcinoma. Int J Oncology 2004, in press

19）Shimada H, Ochiai T, Nomura F：Japan p53 Antibody Research Group. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors；a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer 97：682-689, 2003

20）Svane IM, Pedersen AE, Johnsen HE, et al：Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer；report from a phaseⅠstudy. Cancer Immunol Immunother 53：633-641, 2004

21）van der Burg SH, Menon AG, et al：Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin Cancer Res 8：1019-1027, 2002